U.S. markets closed

Baudax Bio, Inc. (BXRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7650-0.0154 (-1.97%)
At close: 4:00PM EDT
0.7621 -0.00 (-0.38%)
After hours: 04:31PM EDT
Full screen
Loading interactive chart...
  • Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock
    GlobeNewswire

    Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock

    Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern TimeMALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it has scheduled a Special Meeting of shareholders to approve its proposed increase of the number of authorized shares of common stock from 100 million shares to 190 million shares for Tuesday, July 13, 2021

  • Baudax Bio to Participate in the JMP Securities Life Sciences Conference
    GlobeNewswire

    Baudax Bio to Participate in the JMP Securities Life Sciences Conference

    MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a fireside chat virtually at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 4:00 p.m. ET. A live webcast of the fireside chat will be available on the “Presentations” page withi

  • Baudax Bio’s ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market
    GlobeNewswire

    Baudax Bio’s ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market

    MALVERN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that ANJESO® (meloxicam) injection has achieved approvals at over 100 formularies across the U.S. in under one year of commercialization. ANJESO’s presence on formularies is expected to drive usage through regular availability at both hospitals and ambulatory care centers covered by these fo